TrialSchizophrenia bulletin2016

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

David Walling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.